$AMGN Recent News Amgen ends trials of stomach
Post# of 72741
Posted On: 12/14/2014 11:23:54 AM
$AMGN Recent News
Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com
Updates, advisories and surprises 4:31 p.m. Oct. 27, 2014 - MarketWatch
Amgen net drops, but adjusted earnings beat views 4:14 p.m. Oct. 27, 2014 - Russ Britt
Dividend Challengers: 24 Increases Expected By February 28 3:17 p.m. Dec. 13, 2014 - Seeking Alpha
bluebird bio (BLUE) Soars on Data from LentiGlobin Study - Analyst Blog 4:45 p.m. Dec. 11, 2014 - Zacks.com
How Can Drugmakers Handle New Pricing Pressures? 4:38 p.m. Dec. 11, 2014 - Investors Business Daily
Mylan Among First to Launch Generic Celebrex - Analyst Blog 4:22 p.m. Dec. 11, 2014 - Zacks.com
Gilead Sciences Bucks Trend In Biotech Short Interest 11:06 a.m. Dec. 11, 2014 - benzinga.com
Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog 3:10 p.m. Dec. 10, 2014 - Zacks.com
AbbVie Reveals Phase II Data on Blood Cancer Drug at ASH (Revised) - Analyst Blog 12:54 p.m. Dec. 10, 2014 - Zacks.com
Allergan Leads The 20 Best Value Bond Trades With A Maturity Of 1 Year Or More 12:17 p.m. Dec. 10, 2014 - Seeking Alpha
Are Investors Signaling Optimism in Biotechs Through Short Interest? 9:24 a.m. Dec. 10, 2014 - 247WallSt.com
Bristol-Myers sets up collaborative cancer study in Japan 7:36 a.m. Dec. 10, 2014 - Seeking Alpha
Dynavax & AstraZeneca Alter Agreement for Asthma Product - Analyst Blog 6:20 p.m. Dec. 9, 2014 - Zacks.com
Alnylam Reports Positive Initial Phase I Data on ALN-AT3 - Analyst Blog 5:20 p.m. Dec. 9, 2014 - Zacks.com
Pharmacyclics Presents Imbruvica Data at the ASH Meeting - Analyst Blog 5:10 p.m. Dec. 9, 2014 - Zacks.com
Amgen Successfully Expands Xgeva Label in the U.S. - Analyst Blog 5:00 p.m. Dec. 9, 2014 - Zacks.com
Celgene Up on Positive Revlimid Data Presented at ASH - Analyst Blog 4:40 p.m. Dec. 9, 2014 - Zacks.com
Novartis Reports Encouraging Data on Biosimilar of Neupogen - Analyst Blog 3:15 p.m. Dec. 9, 2014 - Zacks.com
Amgen Unveils Positive Results from Blood Cancer Studies - Analyst Blog 7:05 p.m. Dec. 8, 2014 - Zacks.com
Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry - Analyst Blog 6:50 p.m. Dec. 8, 2014 - Zacks.com
Amgen and Merck team up in melanoma 5:04 p.m. Dec. 8, 2014 - Seeking Alpha
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA For Advanced Melanoma 3:21 p.m. Dec. 8, 2014 - benzinga.com
Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Dec. 11, 2014 - PR Newswire - PRF
Frequentz Broadens Expertise in Traceability Space with Addition of Lew Kontnik as Strategic Advisor 4:05 p.m. Dec. 10, 2014 - PR Newswire - PRF
Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 9:00 p.m. Dec. 8, 2014 - PR Newswire - PRF
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma 4:20 p.m. Dec. 8, 2014 - PR Newswire - PRF
FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy 9:00 a.m. Dec. 8, 2014 - PR Newswire - PRF
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors 8:01 a.m. Dec. 8, 2014 - GlobeNewswire
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 1:00 p.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 11:00 a.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition 7:00 p.m. Dec. 3, 2014 - PR Newswire - PRF
Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources 4:30 p.m. Dec. 3, 2014 - PR Newswire - PRF
FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 3:48 p.m. Dec. 3, 2014 - PR Newswire - PRF
Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment 9:06 a.m. Dec. 2, 2014 - Marketwired
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment 4:06 p.m. Nov. 27, 2014 - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 25, 2014 - PR Newswire - PRF
Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer 9:15 a.m. Nov. 24, 2014 - PR Newswire - PRF
Biotech Stocks in Motion - Amgen, Merrimack Pharma, NPS Pharma, BioMarin Pharma, and Regeneron Pharma 8:45 a.m. Nov. 24, 2014 - PR Newswire - PRF
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel 8:01 a.m. Nov. 19, 2014 - BusinessWire - BZX
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 4:00 p.m. Nov. 18, 2014 - PR Newswire - PRF
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza 4:05 p.m. Nov. 17, 2014 - GlobeNewswire
Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com
Updates, advisories and surprises 4:31 p.m. Oct. 27, 2014 - MarketWatch
Amgen net drops, but adjusted earnings beat views 4:14 p.m. Oct. 27, 2014 - Russ Britt
Dividend Challengers: 24 Increases Expected By February 28 3:17 p.m. Dec. 13, 2014 - Seeking Alpha
bluebird bio (BLUE) Soars on Data from LentiGlobin Study - Analyst Blog 4:45 p.m. Dec. 11, 2014 - Zacks.com
How Can Drugmakers Handle New Pricing Pressures? 4:38 p.m. Dec. 11, 2014 - Investors Business Daily
Mylan Among First to Launch Generic Celebrex - Analyst Blog 4:22 p.m. Dec. 11, 2014 - Zacks.com
Gilead Sciences Bucks Trend In Biotech Short Interest 11:06 a.m. Dec. 11, 2014 - benzinga.com
Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog 3:10 p.m. Dec. 10, 2014 - Zacks.com
AbbVie Reveals Phase II Data on Blood Cancer Drug at ASH (Revised) - Analyst Blog 12:54 p.m. Dec. 10, 2014 - Zacks.com
Allergan Leads The 20 Best Value Bond Trades With A Maturity Of 1 Year Or More 12:17 p.m. Dec. 10, 2014 - Seeking Alpha
Are Investors Signaling Optimism in Biotechs Through Short Interest? 9:24 a.m. Dec. 10, 2014 - 247WallSt.com
Bristol-Myers sets up collaborative cancer study in Japan 7:36 a.m. Dec. 10, 2014 - Seeking Alpha
Dynavax & AstraZeneca Alter Agreement for Asthma Product - Analyst Blog 6:20 p.m. Dec. 9, 2014 - Zacks.com
Alnylam Reports Positive Initial Phase I Data on ALN-AT3 - Analyst Blog 5:20 p.m. Dec. 9, 2014 - Zacks.com
Pharmacyclics Presents Imbruvica Data at the ASH Meeting - Analyst Blog 5:10 p.m. Dec. 9, 2014 - Zacks.com
Amgen Successfully Expands Xgeva Label in the U.S. - Analyst Blog 5:00 p.m. Dec. 9, 2014 - Zacks.com
Celgene Up on Positive Revlimid Data Presented at ASH - Analyst Blog 4:40 p.m. Dec. 9, 2014 - Zacks.com
Novartis Reports Encouraging Data on Biosimilar of Neupogen - Analyst Blog 3:15 p.m. Dec. 9, 2014 - Zacks.com
Amgen Unveils Positive Results from Blood Cancer Studies - Analyst Blog 7:05 p.m. Dec. 8, 2014 - Zacks.com
Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry - Analyst Blog 6:50 p.m. Dec. 8, 2014 - Zacks.com
Amgen and Merck team up in melanoma 5:04 p.m. Dec. 8, 2014 - Seeking Alpha
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA For Advanced Melanoma 3:21 p.m. Dec. 8, 2014 - benzinga.com
Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Dec. 11, 2014 - PR Newswire - PRF
Frequentz Broadens Expertise in Traceability Space with Addition of Lew Kontnik as Strategic Advisor 4:05 p.m. Dec. 10, 2014 - PR Newswire - PRF
Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 9:00 p.m. Dec. 8, 2014 - PR Newswire - PRF
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma 4:20 p.m. Dec. 8, 2014 - PR Newswire - PRF
FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy 9:00 a.m. Dec. 8, 2014 - PR Newswire - PRF
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors 8:01 a.m. Dec. 8, 2014 - GlobeNewswire
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 1:00 p.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 11:00 a.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition 7:00 p.m. Dec. 3, 2014 - PR Newswire - PRF
Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources 4:30 p.m. Dec. 3, 2014 - PR Newswire - PRF
FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 3:48 p.m. Dec. 3, 2014 - PR Newswire - PRF
Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment 9:06 a.m. Dec. 2, 2014 - Marketwired
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment 4:06 p.m. Nov. 27, 2014 - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 25, 2014 - PR Newswire - PRF
Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer 9:15 a.m. Nov. 24, 2014 - PR Newswire - PRF
Biotech Stocks in Motion - Amgen, Merrimack Pharma, NPS Pharma, BioMarin Pharma, and Regeneron Pharma 8:45 a.m. Nov. 24, 2014 - PR Newswire - PRF
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel 8:01 a.m. Nov. 19, 2014 - BusinessWire - BZX
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 4:00 p.m. Nov. 18, 2014 - PR Newswire - PRF
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza 4:05 p.m. Nov. 17, 2014 - GlobeNewswire
(0)
(0)